Benjamin Adam Weinberg, MD| Gastrointestinal Medical Oncology, Hematology Oncology | MedStar Health
About me
Dr. Weinberg is an Associate Professor of Medicine and Attending Physician specializing in gastrointestinal medical oncology and sarcoma. Dr. Weinberg is focused on developing new therapies for colorectal and pancreatic cancers by translating research from animal models into early phase clinical trials in humans. He also studies young patients with colorectal cancer and their microbiome in order to understand the dramatic rise in incidence of left-sided colon and rectal cancers in this population.
Dr. Weinberg obtained his undergraduate degree in biomedical science at the University of Pennsylvania in 2007 and his MD at the Keck School of Medicine of the University of Southern California in 2011. He completed his post-graduate medical training at MedStar Georgetown University Hospital with a residency in internal medicine in 2014 and a fellowship in hematology and oncology in 2017 where he served as the Chief Fellow from 2016 to 2017.
Throughout his medical career, Dr. Weinberg has worked exhaustively to make sure that patients are heard and that they receive the highest quality of care. His training as a resident and fellow at Georgetown leads him in the pursuit of cura personalis (“care for the whole person”), and he brings this mindset every day into the clinic and all his work with patients.
Clinical areas of focus
- Colorectal Malignancy
- Esophageal Cancer
- Gastrointestinal (GI) Cancer
- Gastrointestinal (GI) Stromal Tumors
- Hepatoblastoma
- Liver Cancer
- Liver Metastases
- Pancreas Cancer
- Rectal Cancer
- Small Bowel Cancer
Conditions and procedures
Conditions I treat
- Abdominal Cancer
- Anal Cancer
- Anorectal Cancer
- Appendiceal Cancer
- Atypical Lipomatous Tumor
- Bile Duct Mass
- Carcinoid Of Stomach
- Carcinoid Tumor
- Carcinoid Tumor Of Pancreas
- Cholangiocarcinoma
- Colorectal Malignancy
- Esophageal Cancer
- Gallbladder Cancer
- Gastrin Secreting Tumor Of Pancreas
- Gastroesophageal Junction Cancer
- Gastrointestinal (GI) Cancer
- Gastrointestinal (GI) Stromal Tumors
- Hepatobiliary Malignancies
- Hepatoblastoma
- Islet Cell Tumor
- Kras Mutation
- Liver Cancer
- Liver Mass
- Liver Metastases
- Lynch Syndrome
- Malignant Carcinoid Tumor Of Colon
- Malignant Mesenchymoma
- Malignant Neoplasm Of Pancreatic Duct
- Malignant Peripheral Nerve Sheath Tumor
- Malignant Primitive Neuroectodermal Tumor (PNET)
- Malignant Rectal Neoplasm
- Malignant Schwannoma
- Malignant Tenosynovial Giant Cell Tumor
- Malignant Tumor Of Extrahepatic Bile Duct
- Metastatic Colon Cancer
- Osteosarcoma
- Pancreas Cancer
- Pancreas Head Cancer
- Pancreas Tail Cancer
- Pancreatic Mass
- Pecoma
- Peutz Jeghers Syndrome
- Pseudomyxoma Peritonei
- Radiation Associated Sarcomas
- Rectal Cancer
- Rectal Carcinoma In Situ
- Recurrent Colorectal Cancer
- Retiform Hemangioendothelioma
- Side Effects Of Cancer Treatment
- Small Bowel Cancer
- Small Intestine Cancer
- Solitary Fibrous Tumor
- Stomach Cancer
- Synovial Sarcoma
- Unclassified Sarcoma
- Undifferentiated Pleomorphic Sarcoma
- Undifferentiated Sarcoma
- Uterine Sarcoma
Procedures I perform
- Adjuvant Chemotherapy
- Biologic Therapy For Gastrointestinal Diseases
- Biological Targeted Therapy
- Cancer Chemotherapy
- Cancer Genomics
- Cancer Immunotherapy
- Chemoradiation
- Colon Cancer Chemotherapy
- Colon Cancer Genomics
- Gallbladder Cancer Genomics
- Gastrointestinal (GI) Cancer Genomics
- Liver Cancer Genomics
- Pancreatic Cancer Genomics
- Rectal Cancer Genomics
- Stomach Cancer Genomics
Practice locations
Distance from Change LocationEnter your Location
3800 Reservoir Road Northwest Lombardi Cancer Center Washington, DC, 20007
202-444-2223Fax 202-444-1229
Insurance
MedStar Health accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Health, please call your insurance company.
-
List of insurance plans we accept
- UnitedHealthcare and AARP Medicare Complete Plans/ UHC Group Medicare Advantage Plans HMO, POS, PPO
- Kaiser Permanente Medicare Advantage Signature and Select (aka Senior Advantage)
- Blue Choice Advantage & Healthy Blue (HMO, POS)
- United Healthcare Options (PPO) (includes Empire PPO, GEHA, Compass Rose)
- Private Health Care Systems (PHCS) (PPO)
- Kaiser Permanente Select
- Kaiser PermanenteSelect-Added Choice
- Kaiser Permanente Medicare Plus (Medicare Supplemental Plan)
- Kaiser MD Medicaid MCO
- Medicare Fee for Service
- UnitedHealthcare Medicare Adv/Special Needs Plans
- Kaiser Virginia Premier
- CFBCBS EPO
- UHC Community Plan of MD
- Kaiser Permanente Flexible Choice POS
- Kaiser Permanente Signature-Added Choice
- CFBCBS Federal Employee Program (Std/Basic PPO/Blue Focus)
- Kaiser Permanente Signature
- Innovation Health: Indemnity
- Select HMO/HealthFund/Health Network
- POS OA & OA Plus
- Aetna HMO-Open Access/Select OA/HealthFund/Health Network Option OA
- Open POS II
- Aetna Elect Choice/ Open Access (POS)
- CFBSBC Blue Preferred PPO
- Open EPO Plus
- Aetna Managed Choice (POS)
- PPO and PPO Plus
- CIGNA HMO Open Access (OA)
- Open HMO
- Aetna Innovations: HMO & EPO Plus
- CFBCBS Blue Choice Opt Out Open Access
- Aetna HMO
- HealthyBlue PPO
- Aetna Open Choice (PPO)
- Innovation Health: Open POS Plus
- Innovation Health: POS
- Network OA
- United Healthcare Choice
- Innovation Health: PPO
- CIGNA EPO
- Aetna Managed Choice Open Access (POS)
- Innovation Health: Open Network Only Plus
- Opoen HMO Option
- Choice POS & Choice POS II
- BlueChoice Open Access
- Innovation Health: POS Plus
- Choice Fund PPO
- Aetna Traditional Choice (PPO)
- Coventry Health Care National Network PPO
- Aetna Worker's Compensation Network
- Mamsi Life & Health (Indem./PPO)
- Optimum Choice Preferred (POS) & OCI Direct (HMO)
- M.D. IPA Preferred (POS)
- M.D. IPA (HMO)
- United Student Resources
- United Healthcare Choice Plus
- United Healthcare Select Plus (POS)
- United Healthcare Select HMO - EPO/NPP
- MedStar Select (MedStar Associates' Plan)
- MedStar Family Choice - Maryland Health Choice
- Tricare for Life (Medicare Supplemental Plan)
- Tricare Prime
- FIRST HEALTH
- First Health PPO
- Coventry of Delaware HMO/PPO
- Coventry Health Care of Virginia
- CIGNA Indemnity
- Great-West Healthcare POS/CIGNA
- CIGNA POS/Network POS
- CIGNA HMO & Network (HMO)
- CFBCBS (NCA) Indemnity
- CFBCBS Maryland Indemnity or PPO
- CFBCBS Maryland Point of Service Plan (MPOS)
- CFBCBS Blue Choice Opt Out Plus Open Access (POS)
- CFBCBS BlueChoice HMO
- Aetna Medicare Advantage HMO & PPO Plans
- Aetna Student Health Insurance
- Aetna Quality Point of Service (POS)
- Aetna Elect Choice/ EPO (Aetna Health Fund) Innovation Health: Network Only Plus
Videos
Education
Board Certification: American Board of Internal Medicine, Medical Oncology
Board Certification: American Board of Internal Medicine, Hematology
Board Certification: American Board of Internal Medicine, Internal Medicine
Fellowship Program: MedStar Georgetown University Hospital (2017)
Internship/Residency: MedStar Georgetown University Hospital (2014)
Medical School: Keck School of Medicine of the University of Southern California (2011)
Awards
- HemeOnc Today's Next Gen Innovator, June 2019
- First Place, Fellow Clinical Research Award, Georgetown Department of Medicine Research Day
- 2017 Conquer Cancer Foundation Gastrointestinal Cancers Symposium Merit Award
- 2016 Conquer Cancer Foundation of ASCO Young Investigator Award
- AACR/ASCO Workshop on Methods in Clinical Cancer Research Invited Participant, Vail, CO
- Donald E. and Delia B. Baxter Foundation Award
- Medical Student Summer Research Fellowship, Keck School of Medicine
- Dean’s Recognition, Keck School of Medicine of the University of Southern California
- NIH Summer Intramural Research Training Award Fellowships
Hospital affiliations
News and publications
Original Papers
Reviews or Editorials
- Weinberg BA, Winslow RW, Bayasi M, Krainock MR, Olshan PM, Billings PR, Aleshin A, George GV. Early detection of circulating tumor DNA post-operatively enables discovery of resectable metastatic disease in a patient with colon cancer. Case Reports in Oncology, 2021; in press.
- Arai H, Elliott A, Millstein J, Xiu J, Ou F, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanish N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Lockhart AC, Shields AF, Abraham JP, Magee D, Stafford P, Zhang J, Venook AP, Korn WM, Lenz HJ. Molecular characteristics and clinical outcomes of patients with neurofibromin 1-altered metastatic colorectal cancer. Oncogene, 2021; epub ahead of print. doi: 10.1038/s41388-021-02074-z. PubMed PMID: 34728807.
- Malchiodi ZX, Cao H, Gay MD, Safronenka A, Bansal S, Tucker RD, Weinberg BA, Cheema A, Shivapurkar N, Smith JP. Cholecystokinin receptor antagonist improves efficacy of chemotherapy in murine pancreatic cancer by altering tumor microenvironment. Cancers (Basel), 2021 Sep;13(10):4949. doi: 10.3390/cancers13194949. PubMed PMID: 34638432.
- Armstrong SA, Malley R, Wang H, Lenz HJ, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, Hwang JJ, Philip PA, Shields AF, Marshall JL, Salem ME‡, Weinberg BA‡. Molecular characteristics of anal squamous cell carcinoma. Journal of Gastrointestinal Oncology, 2021; epub ahead of print (‡Co-senior authors). doi: 10.21037/jgo-20-610.
- Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, Weinberg BA, VanderWalde AM, Tesfaye A, Raymond VM, Miron B, Tarcic G, Zelichov O, Broaddus RR, Ng PKS, Jeong KJ, Tsang YH, Mills GB, Overman MJ, Grothey A, Marshall JL, Kopetz S. Clinical and functional characterization of atypical KRAS/NRAS mutations in metastatic colorectal cancer. Clinical Cancer Research, 2021; epub ahead of print. doi: 10.1158/1078-0432.CCR-21-0180. PubMed PMID: 34117033.
- Lou E, Xiu J, Baca Y, Nelson AC, Weinberg BA, Beg MS, Salem ME, Lenz HJ, Philip P, El-Deiry W, Korn WM. Expression of immuno-oncologic biomarkers is enriched in colorectal cancers and other solid tumors harboring the A59T variant of KRAS. Cells, May 21;10(6):1275. doi: 10.3390/cells10061275. PubMed PMID: 3406399; PubMed Central PMCID: PMC8224072.
- Wang J, Xiu J, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Oberley M, Spetzler D, Shen L, Korn WM, Lenz HJ. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. Annals of Oncology, 2021; epub ahead of print.
- Arai H, Elliott A, Xiu J, Wang J, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Marshall JL, Lockhart AC, Stafford P, Zhang J, Moretto R, Cremolini C, Korn WM. The landscape of the DNA damage response pathways in colorectal cancer. Clinical Cancer Research, 2021; epub ahead of print.
- Borden BA, Baca Y, Xiu J, Tavora F, Winer I, Weinberg BA, VanderWalde AM, Darabi S, Korn WM, Mazar AP, Giles FJ, Crawford L, Saftran H, El-Deiry WS. The landscape of glycogen synthase kinase-3 beta (GSK-3b) genomic alterations in cancer. Molecular Cancer Therapeutics, 2020; epub ahead of print. doi: 10.1158/1535-7163.MCT_20-0497. PubMed PMID: 33087512.
- Cadranel J, Liu SV, Duruisseaux M, Branden E, Goto Y, Weinberg BA, Hening C, Schlenk RF, Cheema P, Jones MR, Drilon A, Trombetta D, Muscarella LA, Tolba K, Gounant V, Cseh A, Solca F, Laskin JJ, Renouf DJ. Therapeutic potential of afatinib in NRG1 fusion-driven solid tumors: a case series. The Oncologist, 2020 Aug; epub ahead of print. doi: 10.1634/theoncologist.2020-0379. PMID: 32852072.
- Weinberg BA, Wang H, Witkiewicz AK, Marshall JL, He AR, Vail P, Knudsen ES, Pishvaian MJ. A phase I study of ribociclib plus everolimus in patients with metastatic pancreatic adenocarcinoma refractory to chemotherapy. Journal of Pancreatic Cancer, 2020;6(1):1-10. doi: 10.1089/pancan.2020.0005. PubMed Central PMCID: PMC7337242.
- Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR. A phase I/II study of veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer. Clinical Cancer Research, 2020 Oct;26(19):5092-5101. doi: 10.1158/1078-0432.CCR-20-1301.
- Mody K, Starr J, Saul M, Poorman K, Weinberg BA, Salem ME, VanderWalde A, Shields AF. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. Journal of Gastrointestinal Oncology, 2019 Dec;10(6):1099-1109. doi: 10.21037/jgo.2019.08.08. PubMed PMID: 31949927; PubMed Central PMCID: PMC6955012.
- Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K, Salem ME, Pishvaian MJ, Holcombe RF, Marshall JL, Morse MA. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. Journal of Gastrointestinal Oncology, 2019 Aug;10(4):652-662. doi: 10.21037/jgo.2018.08.18. PubMed PMID: 31392046; PubMed Central PMCID: PMC6657312.
- Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. European Journal of Cancer, 2018 Nov;103:205-213. doi: 10.1016/j.ejca.2018.08.020. Epub 2018 Sep 27. PubMed PMID: 30268921.
- Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME. Impact of patient age on molecular alterations of the left-sided colorectal tumors. The Oncologist, 2019 Mar;24(3):319-326. doi: 10.1634/theoncologist.2018-0117. Epub 2018 July 17. PubMed PMID: 30018131; PubMed Central PMCID: PMC6519749.
- Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL. Immuno-oncology biomarkers for gastric and gastroesophageal junction adenocarcinoma: why PD-L1 testing may not be enough. The Oncologist, 2018 Oct;23(10):1171-1177. doi: 10.1634/theoncologist.2018-0034. Epub 2018 Apr 27. PubMed PMID: 29703766; PubMed Central PMCID: PMC6263127.
- Salem ME, Puccini A, Grothey A, Raghavan D, Goldberg RM, Xiu J, Korn WM, Weinberg BA, Hwang JJ, Shields AF, Marshall JL, Philip PA, Lenz HJ. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Molecular Cancer Research, 2018 May;16(5):805-812. doi: 10.1158/1541-7786.MCR-17-0735. Epub 2018 Mar 9. PubMed PMID: 29523759; PubMed Central PMCID: PMC6833953.
- ‡Salem ME, ‡Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017 Oct 17;8(49):86356-86368. doi: 10.18632/oncotarget.21169. Epub 2017 Sep 21. PubMed PMID: 29156800; PubMed Central PMCID: PMC5689690. (‡Co-first authors).
- Weinberg BA, Gowen K, Lee TK, Ou SH, Bristow R, Krill L, Almira-Suarez MI, Ali SM, Miller VA, Liu SV, Klempner SJ. Comprehensive genomic profiling aids in distinguishing metastatic recurrence from second primary cancers. The Oncologist, 2017 Feb;22(2):152-157. doi: 10.1634/theoncologist.2015-0511. Epub 2017 Feb 13. PubMed PMID: 28193735; PubMed Central PMCID: PMC5330711.
- Weinberg BA, Wang H, Yang X, Wu CS, Pishvaian MJ, He AR, Marshall JL, Hwang JJ. Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy, a retrospective cohort study. Gastrointestinal Cancer Research, 2014 May;7(3-4):91-97. PubMed PMID: 25276262; PubMed Central PMCID: PMC4171974.
- El-Chemaly S, Malide D, Zudaire E, Ikeda Y, Weinberg BA, Pacheco-Rodriguez G, Rosas IO, Aparicio M, Ren P, MacDonald SD, Wu HP, Nathan SD, Cuttitta F, McCoy JP, Gochuico BR, Moss J. Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2009 Mar;106(10):3958-3963. doi: 10.1073/pnac.0813368106. Epub 2009 Feb 23. PubMed PMID: 19237567; PubMed Central PMCID: PMC2646625.
Reviews or Editorials
- Xiao J, Pohlmann PR, Issacs C, Weinberg BA, He AR, Schlegel R, Agarwal S. Circulating tumor cells: technologies and their clinical potential in cancer metastasis. Biomedicines, 2021 Aug;9(9):1111. doi: 10.3390/biomedicines9091111. PubMed PMID: 34572297.
- REACCT Collaborative, Zaborowski AM, A....Weinberg BA..., Wells C, Wolthuis A, Xynos E, You N, Zakharenko A, Zeballos J, Winter DC. Characteristics of early-onset vs late-onset colorectal cancer: a review. JAMA Surgery, 2021; epub ahead of print. doi: 10.1001/jamasurg.2021.2380. PubMed PMID: 34190968.
- Armstrong SA, Malley R, Weinberg BA. Molecular profiling in metastatic colorectal cancer. Oncology (Williston Park), 2020 Sep;34(9):352-355. doi: 10.46883/ONC.2020.3409.0352. PubMed PMID: 32965665.
- Armstrong SA, Malley R, Weinberg BA. Glimmers of hope: new strategies for overcoming resistance in patients with BRAF V600E-mutated metastatic colorectal cancer. Oncology & Hematology Review (US), 2020 Jul;16(1):31-35.
- Mukherji R, Weinberg BA. The gut microbiome and potential implications for early-onset colorectal cancer. Colorectal Cancer, 2020 Epub 2020 Oct;9(1). doi: 10.2217/crc-2020-0007.
- Marshall JL, Yarden RI, Weinberg BA. Colorectal cancer in the age of coronavirus – strategies to reduce risk and maintain benefit. Colorectal Cancer, Epub 2020 Apr;9(1). doi: 10.2217/crc-2020-0010. PubMed Central PMCID: PMC7170009.
- Weinberg BA, Hameed R, Marshall JL. Biomarkers for immune therapy in gastrointestinal cancers. Clinical Advances in Hematology & Oncology, 2019 Feb;17(2):109-119. PubMed PMID: 30845114.
- Weinberg BA, Marshall JL. Colon cancer in young adults: trends and their implications. Current Oncology Reports, 2019 Jan 18;21(1):3. doi: 10.1007/s11912-019-0756-8. PubMed PMID: 30659375.
- Weinberg BA. Anti-EGFR therapy in right-sided metastatic colorectal cancer: right or wrong? Journal of the National Comprehensive Cancer Network, 2018 Dec;16(12):1547-1548. doi: 10.6004/jnccn.2018.7107. PubMed PMID: 30545999.
- Puthiamadathil JM, Weinberg BA. Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil. Cancer Management and Research, 2017 Oct;9:461-469. doi: 10.2147/CMAR.S113320. PubMed PMID: 29056855; PubMed Central PMCID: PMC5635852.
- Serzan MT, Weinberg BA, Salem ME. Second-line therapy in advanced colorectal cancer: EGFR vs. continuation of VEGF inhibition. Current Colorectal Cancer Reports, 2017 Sep 18;13(6):411-418. doi: 10.1007/s11888-017-0388-z.
- Weinberg BA, Hartley M, Salem ME. Precision medicine in metastatic colorectal cancer: relevant carcinogenic pathways and targets. Part 1: biologic therapy targeting epidermal growth factor receptor and vascular endothelial growth factor. Oncology (Williston Park), 2017 Jul;31(7):539-548. PubMed PMID: 28712098.
- Weinberg BA, Hartley M, Salem ME. Precision medicine in metastatic colorectal cancer: relevant carcinogenic pathways and targets. Part 2: approaches beyond first-line therapy, and novel biologic agents under investigation. Oncology (Williston Park), 2017 Jul;31(7):573-580. PubMed PMID: 28712102.
- Weinberg BA, Marshall JL, Salem ME. The growing challenge of young adults with colorectal cancer. Oncology (Williston Park), 2017 May;31(5):381-389. PubMed PMID: 28516436.
- Weinberg BA, Philip PA, Salem ME. Evolving standards of care for resected pancreatic cancer. Clinical Advances in Hematology & Oncology, 2017 Feb;15(2):141-150. PubMed PMID: 28398285.
- Weinberg BA, Marshall JL, Salem ME. Trifluridine/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer. Clinical Advances in Hematology & Oncology, 2016 Aug;14(8):630-638. PubMed PMID: 27487107.
- Weinberg BA, Marshall JL, Hartley M, Salem ME. A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer. Clinical Advances in Hematology & Oncology, 2016 Feb;14(2):116-128. PubMed PMID: 27057810.
- Weinberg BA, Yabar CS, Brody JR, Pishvaian MJ. Current standards and novel treatment options for metastatic pancreatic adenocarcinoma. Oncology (Williston Park), 2015 Nov;29(11):809-820, 886. PubMed PMID: 26573060.